<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713284</url>
  </required_header>
  <id_info>
    <org_study_id>KTXP_US28_MYFIIRP07</org_study_id>
    <nct_id>NCT00713284</nct_id>
  </id_info>
  <brief_title>Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic</brief_title>
  <acronym>MYFIIRP</acronym>
  <official_title>A Pilot Study to Evaluate the Safety and Efficacy of Mycophenolate Sodium (Myfortic®) in Combination With Sirolimus (Rapamune®) in Stable Renal Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of Myfortic and sirolimus&#xD;
      is effective at preventing rejection while preserving kidney function in stable kidney&#xD;
      transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One-year graft survival after renal transplantation dramatically improved with the addition&#xD;
      of calcineurin inhibitors (tacrolimus or cyclosporine) to maintenance immunosuppression&#xD;
      regimens. Much of this improvement in early graft survival has been attributed to the&#xD;
      efficacy of the calcineurin inhibitors in preventing early acute rejection episodes. However,&#xD;
      long-term graft survival has not improved to as great of a magnitude as the improvements in&#xD;
      short-term survival. In addition, research shows progressive decline in kidney function&#xD;
      throughout the years post-transplantation. Clinical research now focuses on improving long&#xD;
      term graft survival while maintaining long-term kidney function.&#xD;
&#xD;
      The leading cause of graft loss has been attributed to chronic allograft nephropathy (CAN).&#xD;
      Risk factors for CAN include: prolonged ischemia time, delayed graft function, acute&#xD;
      rejection episodes and calcineurin inhibitor nephrotoxicity (CIN). CIN has been identified as&#xD;
      the most common identifiable contributor to CAN and the chief cause of late histologic injury&#xD;
      and ongoing decline in renal function. At 10 years post-transplant, CIN has been found to be&#xD;
      universally prevalent.&#xD;
&#xD;
      Calcineurin inhibitor minimization and elimination studies have sought to improve long-term&#xD;
      allograft function by minimizing exposure to these nephrotoxic agents. Studies have&#xD;
      demonstrated that early withdrawal of cyclosporine from a cyclosporine, sirolimus and steroid&#xD;
      immunosuppression regimen at 3 months post-transplant improved renal function and graft&#xD;
      survival at 48 months post-transplant. Other studies have demonstrated diminished prevalence&#xD;
      of CAN at 2 years post-transplant in those patients maintained on sirolimus as compared with&#xD;
      cyclosporine. Kidney function was also significantly improved with lower serum creatinine and&#xD;
      higher GFR in the sirolimus maintenance group.&#xD;
&#xD;
      Sirolimus is a macrolide antibiotic immunosuppressive agent that exerts its mechanism of&#xD;
      action by inhibiting the mTOR signaling cascade. In clinical trials, sirolimus was found to&#xD;
      lack nephrotoxic effects when compared to cyclosporine. In kidney transplantation, multiple&#xD;
      studies have demonstrated safety and efficacy of sirolimus in calcineurin inhibitor avoidance&#xD;
      and withdrawal protocols.&#xD;
&#xD;
      Myfortic® (mycophenolate acid) is an enteric coated formulation of mycophenolic acid (MPA)&#xD;
      approved for the prevention of rejection in kidney transplant recipients in combination with&#xD;
      cyclosporine and corticosteroids. Myfortic® has no documented nephrotoxic effects.&#xD;
      Mycophenolate mofetil (MMF), a prodrug of MPA also does not demonstrate nephrotoxic effects.&#xD;
      Early studies have demonstrated therapeutic equivalence between Myfortic® and MMF both in de&#xD;
      novo renal transplants and in conversion studies where MMF is converted to Myfortic at least&#xD;
      6 months after renal transplantation. Thus, studies demonstrating safety and efficacy of MMF&#xD;
      with sirolimus in calcineurin inhibitor withdrawal protocols should also hold true using&#xD;
      Myfortic® in such regimen.&#xD;
&#xD;
      This study will assess the safety and efficacy of Myfortic® when used in a simultaneous&#xD;
      sirolimus conversion and calcineurin inhibitor withdrawal regimen in stable renal transplant&#xD;
      recipients. Study subjects will receive immunosuppression consisting of Myfortic®, tacrolimus&#xD;
      and corticosteroids (prednisone) starting the day of transplant. Conversion from tacrolimus&#xD;
      (Prograf) to sirolimus (Rapamune) will occur between 90 and 180 days post cadaver-donor or&#xD;
      living-donor renal transplant. All participants will be converted from tacrolimus to&#xD;
      sirolimus and remain on Myfortic® and their current corticosteroid taper.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Allograft Function</measure>
    <time_frame>six months</time_frame>
    <description>Renal allograft function will be assessed based on serum creatinine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.</description>
    <arm_group_label>Study</arm_group_label>
    <other_name>Rapamune</other_name>
    <other_name>rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria I (-1 to 7 days post renal allograft transplant):&#xD;
&#xD;
          -  Male or female patient 18 years of age or older.&#xD;
&#xD;
          -  Patient has been fully informed of study procedures and requirements, has signed an&#xD;
             IRB approved consent form and is willing and able to follow study procedures.&#xD;
&#xD;
        Exclusion Criteria I (-1 to 7 days post renal allograft transplant):&#xD;
&#xD;
          -  Patient has previously received an organ transplant.&#xD;
&#xD;
          -  Patient has an identified donor specific antibody prior to transplant&#xD;
&#xD;
          -  Patient is known to be seropositive for the human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Patient has active Hepatitis C or B infection documented by a positive DNA PCR.&#xD;
             Patients who are seropositive for Hepatitis C virus (HCV) or B virus (HBV) but have&#xD;
             negative HCV-RNA or HBV-DNA by PCR may be included.&#xD;
&#xD;
          -  Patient has a current malignancy or a history of malignancy within the past 5 years,&#xD;
             except non-metastatic basal or squamous cell carcinoma of the skin that has been&#xD;
             treated successfully.&#xD;
&#xD;
          -  Patient has an uncontrolled infection or unstable medical condition that could&#xD;
             interfere with the study objectives.&#xD;
&#xD;
          -  Patient is currently taking or has been taking an investigational drug in the past 30&#xD;
             days.&#xD;
&#xD;
          -  Patient has a known hypersensitivity to sirolimus or Myfortic®.&#xD;
&#xD;
          -  Patient is pregnant or lactating.&#xD;
&#xD;
          -  Patient is unlikely to comply with the visits scheduled in the protocol.&#xD;
&#xD;
          -  Patient has any form of substance abuse, psychiatric disorder or a condition that, in&#xD;
             the opinion of the investigator, may invalidate communication with the investigator.&#xD;
&#xD;
        Inclusion Criteria II (90 - 180 days post renal allograft transplant):&#xD;
&#xD;
          -  Patient is 90 to 180 days after having received a primary living- or cadaver-donor&#xD;
             renal allograft&#xD;
&#xD;
          -  Patient has been maintained on a regimen of tacrolimus, Myfortic® and corticosteroids&#xD;
             prior to study enrollment.&#xD;
&#xD;
          -  Patient has a stable allograft defined as calculated GFR &gt; 30 mL/min using Nankivell&#xD;
             equation.&#xD;
&#xD;
          -  Patient has been fully informed of study procedures and requirements, has signed an&#xD;
             IRB approved consent form and is willing and able to follow study requirements.&#xD;
&#xD;
          -  Female patients of child bearing potential must use at least one reliable form of&#xD;
             contraception unless they are status post bilateral tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy. Effective contraception must be used for the duration of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria II (90 - 180 days post renal allograft transplant):&#xD;
&#xD;
          -  Patient has experienced an acute graft rejection of ≥ Banff '97 1b or humoral&#xD;
             rejection as determined by biopsy within the first 90 days post-transplant&#xD;
&#xD;
          -  Patient has experienced an acute graft rejection of ≤ Banff 97 1a as determined by&#xD;
             biopsy within 30 days prior to Baseline visit.&#xD;
&#xD;
          -  Patient has untreated hypercholesterolemia defined as triglycerides &gt; 300 or total&#xD;
             cholesterol &gt;200 within the previous 30 days.&#xD;
&#xD;
          -  Patient is currently (&lt; 7 days) leukopenic defined as WBC &lt; 3,000 cells/mL or&#xD;
             thrombocytopenic defined as platelets &lt; 100,000 cells/mL.&#xD;
&#xD;
          -  Patient has significant liver disease, defined as having during the past 30 days&#xD;
             continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the&#xD;
             upper value of normal range.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V. Ram Peddi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Pacific Medical Center; Barry S. Levin, MD Department of Transplantation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Merion RM, White DJ, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med. 1984 Jan 19;310(3):148-54.</citation>
    <PMID>6361559</PMID>
  </reference>
  <reference>
    <citation>Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997 Apr 15;63(7):977-83.</citation>
    <PMID>9112351</PMID>
  </reference>
  <reference>
    <citation>Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33.</citation>
    <PMID>14668458</PMID>
  </reference>
  <reference>
    <citation>Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002 Jul;62(1):311-8.</citation>
    <PMID>12081593</PMID>
  </reference>
  <reference>
    <citation>Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005 Jan;18(1):22-8. Erratum in: Transpl Int. 2005 Mar;18(3):369.</citation>
    <PMID>15612979</PMID>
  </reference>
  <reference>
    <citation>Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant. 2004 Nov;4(11):1776-85.</citation>
    <PMID>15476476</PMID>
  </reference>
  <reference>
    <citation>Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation. 2003 Apr 15;75(7):998-1003.</citation>
    <PMID>12698087</PMID>
  </reference>
  <reference>
    <citation>Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Häyry P, Neylan JF; Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant. 2004 Jun;4(6):953-61.</citation>
    <PMID>15147430</PMID>
  </reference>
  <reference>
    <citation>Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Nègre E, Burke JT, Groth CG; Sirolimus European Renal Transplant Study Group. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002 May;2(5):436-42.</citation>
    <PMID>12123209</PMID>
  </reference>
  <reference>
    <citation>Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE; Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001 Sep;145(3):438-45.</citation>
    <PMID>11531834</PMID>
  </reference>
  <reference>
    <citation>Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002 Oct 27;74(8):1070-6.</citation>
    <PMID>12438948</PMID>
  </reference>
  <reference>
    <citation>Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997 Aug;17(2):75-92. Review.</citation>
    <PMID>9285199</PMID>
  </reference>
  <reference>
    <citation>Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M; ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004 Feb;4(2):237-43.</citation>
    <PMID>14974945</PMID>
  </reference>
  <reference>
    <citation>Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004 Feb;4(2):231-6.</citation>
    <PMID>14974944</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2008</study_first_posted>
  <results_first_submitted>July 17, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2020</results_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California Pacific Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>V. Ram Peddi</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data will be shared with other researchers</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus Conversion</title>
          <description>All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29">29 participants were screened but only 13 eligible for conversion and continue in the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus Conversion</title>
          <description>All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.15" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transplant Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Deceased donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Living Unrelated donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Living Related donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Criteria Donor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Expanded Criteria Donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Expanded Criteria Donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to Conversion</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.85" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Allograft Function</title>
        <description>Renal allograft function will be assessed based on serum creatinine</description>
        <time_frame>six months</time_frame>
        <population>One patient experienced an adverse drug reaction and was withdrawn from study treatment one month after conversion</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Conversion</title>
            <description>All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Allograft Function</title>
          <description>Renal allograft function will be assessed based on serum creatinine</description>
          <population>One patient experienced an adverse drug reaction and was withdrawn from study treatment one month after conversion</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (6 months)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus Conversion</title>
          <description>All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Rise in creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitation is small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. V. Ram Peddi</name_or_title>
      <organization>California Pacific Medical Center</organization>
      <phone>415-600-1000</phone>
      <email>peddir@sutterhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

